FDA MedWatch- Avastin (bevacizumab) and Sunitinib Malate- Re

[FutScouro]

figures Provides yet communication on AVANDIA as a OK and remarkable Treatment privilege for annex strain 2 Diabetes Patients

PHILADELPHIA, July 14, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S. sustenance and remedy furnishing (FDA) updated the prescribing communication for AVANDIA(R) (rosiglitazone maleate) to list clinical findings from A Diabetes develpoment advancement stab (accept), a 4- to- 6 year go-to-crumpet examination of AVANDIA versus metformin and glyburide monoremedial lay out in recently diagnosed personification 2 diabetes patients. The share of patients with infair to middling glucose direction at five years was 34 percent with glyburide, 21 percent with metformin and solitary 15 percent with AVANDIA. The alteration between AVANDIA and the comparators was statsitically significant.